Noxopharm Ltd. · ASX:NOX
Noxopharm — Switzer Small & Micro Cap Virtual Investor Day 2021
14 slides from Noxopharm's conference presentation, Mar 29, 2021
Slide 1: ASX Announcement: Presentation for Switzer Small and Micro Cap Virtual Investor Day
For personal use only ASX Announcement | 29 March 2021 Noxopharm Limited (ASX:NOX) Presentation for Switzer Small and Micro Cap Virtual Investor Day Sydney 29 March 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) provides the corporate presentation for the Switze
Slide 2: About Noxopharm and Forward Looking Statements
For personal use only Veyonda is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has three main drug actions – highly selective inhibition of sphingosine kinase, STING signaling and autophagy. Sphingosine kinase inhibition contributes to its dual-acting o
Slide 3: Switzer Small & Micro Cap Virtual Investor Day
For personal use only Noxopharm Limited (ASX:NOX) SWITZER SMALL & MICRO CAP VIRTUAL INVESTOR DAY March 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 4: Disclaimer
Disclaimer For personal use only This presentaKon has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectaKons reflected in the forward looking statements be considered as an offer or invitaKon to subscribe for, or purchase any shares in
Slide 5: Building a drug pipeline on a proprietary platform for cancer and septic shock
Noxopharm is building a pipeline of drugs based For personal use only on a unique and proprietary technology plaGorm for the treatment of cancer and sepHc shock Of est. 55 million deaths globally from disease: • ~ 10 million are from cancer* • ~ 10 million are from septic shock* Tissue injury from:
Slide 6: Link between cancer and septic shock
Link between For personal use only Both involve abnormal immune cancer and and inflammatory sepHc shock responses Common Cancer: underlying • Manipulates the immune system to avoid immune aRack mechanism is • Increases inflammaHon to enable growth and spread altering balance between ceramide and Septi
Slide 7: Veyonda breakthrough COLD to HOT effect
Veyonda® For personal use only breakthrough COLD to HOT effect C Majority of human tumours are COLD (lacking A immune cells) Converting COLD tumors to HOT means that standard anti-cancer treatments should work N better C Veyonda being developed as a combination drug to boost effectiveness of common c
Slide 8: Two clinical studies confirm anti-cancer boost; 3rd key study underway
Veyonda® Two clinical studies confirm anH-cancer boost. For personal use only 3rd key study now underway DARRT program • Veyonda + (low-dose) external beam radiotherapy (EBRT) C • • Phase I study / 25 men / end-stage prostate cancer CombinaHon delivers major boost to anH-cancer effect of EBRT1 A N LuP
Slide 9: Breakthrough potential treatment of cytokine release syndrome
Veyonda® Breakthrough potenHal treatment For personal use only of cytokine release syndrome S Virus causes lung damage E Pre-clinically Veyonda blocks clorng P excessive T cytokine lung response Excessive release of I inflammatory cytokines damage shock C kidney damage S Cytokine release syndrome H (
Slide 10: NOXCOVID-1 clinical study ongoing
Veyonda® NOXCOVID-1 clinical study ongoing For personal use only • 40 paKents with moderate COVID-19 disease S • Requiring hospitalizaKon and low-volume oxygen E supplementaKon P • Dose-escalaKon arm (400-1800 mg) complete • Dose-expansion arm (1800 mg) ongoing T I NOXCOVID program ObjecHve: to demo
Slide 11: Summary
SUMMARY For personal use only Both DARRT and LuPIN have provided clear evidence of proof-of-concept IONIC trial The objecKve of this trial is to use Veyonda to overcome resistance of most cancers to anK-cancer drug Opdivo® (Bristol Myers Squibb) currently with annual sales of USD8 billion Veyonda is
Slide 12: Our commercial end-point for Veyonda
Our commercial end-point for Veyonda For personal use only Noxopharm prepared to take Veyonda all the way to market. However, opportunity as a general booster of most forms of cancer therapy seen as being so large that a partnership potentially is more likely Currently working with Novartis (USD 200
Slide 13: Key metrics as at March 2021
Key metrics For personal use only as at 25 March 2021 Market cap A$182m News Flow (next 6 months) • IONIC-1 and DARRT-2 start paKent recruitment Share price A$0.66 • COVID-19 clinical trial compleKon • Growing first-in-class drug pipeline Issued cap 278.9m shares • Pharmorage (subsidiary) progressing
Slide 14: For further information
For personal use only For further informa2on email: info@noxopharm.com web: www.noxopharm.com twiRer: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 12
Noxopharm — Switzer Small & Micro Cap Virtual Investor Day 2021 on 6ix